Damora Therapeutics, Inc.

Damora Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for hematologic disorders, primarily in Denmark and North America. Its lead product candidate is DMR-001, an investigational monoclonal antibody therapy targeting mutations in CALR, designed to treat essential thrombocythemia. The company also has DMR-002 and DMR-003, both anti-mutCALR-based therapies aimed at addressing the full spectrum of mutCALR myeloproliferative neoplasm (MPN) patients. Additionally, Damora is developing GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. These programs target specific genetic mutations and pathways involved in blood cancers.

Damora Therapeutics, Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol DMRA. The company's stock is traded in U.S. dollars (USD), reflecting its primary listing in the United States. As a U.S.-based biopharmaceutical company with operations in Denmark and North America, its financial reporting and trading currency are in USD.

Damora Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biopharmaceutical company, it focuses on researching and developing innovative therapies for hematologic disorders, including blood cancers such as essential thrombocythemia and acute myeloid leukemia. The biotechnology industry involves using biological processes and genetic engineering to create treatments, and Damora's pipeline includes monoclonal antibodies and small molecule inhibitors targeting specific genetic mutations.

Damora Therapeutics, Inc. is headquartered in Waltham, Massachusetts, United States. The company was founded in 2011 and develops therapies for hematologic disorders in Denmark and North America. Its operations span both the U.S. and Denmark, indicating a transatlantic focus for research and development activities. The primary markets served include the United States and Canada (North America) as well as Denmark, with potential expansion to other regions as its product candidates advance.

Damora Therapeutics' pipeline includes several product candidates targeting hematologic malignancies. The lead candidate is DMR-001, an investigational monoclonal antibody therapy that targets mutations in CALR, intended for the treatment of essential thrombocythemia. The company is also developing DMR-002 and DMR-003, both anti-mutCALR-based therapies designed to address the full spectrum of mutCALR myeloproliferative neoplasm (MPN) patients. Additionally, Damora has GB3226, a small molecule inhibitor of ENL-YEATS and FLT3, for the treatment of acute myeloid leukemia. These candidates are in various stages of development, focusing on genetically defined subsets of blood cancers.